Lara Ramsburg Chief Corporate Affairs Officer Brian Roman Chief Legal Officer Q1 2024 Select Key Product Net Sales, on a Consolidated Basis 22 This document contains proprietary information of Viatris Inc. Unauthorized use, duplication, dissemination or disclosure to third parties is strictly prohibited. © 2024 Viatris Inc. All Rights Reserved. VIATRIS and the Viatris Logo are trademarks of Mylan Inc., a Viatris company. Full-Year 2024 Guidance Items as of May 9, 2024(1) | --- | --- | |--------------------- ...

• Reports Total Revenues of $3.66 Billion; U.S. GAAP Net Earnings of $113.9 Million; Adjusted EBITDA of $1.19 Billion; U.S. GAAP EPS of $0.09; Adjusted EPS of $0.67; U.S. GAAP Net Cash Provided by Operating Activities of $615 Million; and Free Cash Flow of $565 Million for the First Quarter • Reports Fourth Consecutive Quarter of Operational Revenue Growth on a Divestiture-Adjusted Basis[1] • Reaffirms 2024 New Product Revenue Range of $450 Million to $550 Million • Closes Idorsia Transaction, Expanding Por ...

Investors are always looking for stocks that are poised to beat at earnings season and Viatris Inc. (VTRS) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Viatris is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicato ...

Viatris (VTRS) , a global healthcare company, is scheduled to report first-quarter results on May 9, 2024.The company’s earnings beat estimates in three of the trailing four quarters and missed in one, delivering an average surprise of 3.78%. In the last reported quarter, the company missed on earnings by 8.96%.Factors to ConsiderViatris reports revenues under two divisions in terms of product category —brands and generics.Brand business makes up about two-thirds of the company’s portfolio. This category is ...

The market expects Viatris (VTRS) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 9, 2024, might help the stock move higher if these key numbers are better th ...

PITTSBURGH, April 16, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report its first quarter 2024 financial results on Thursday, May 9, 2024, before the open of the U.S. financial markets. Chief Executive Officer Scott A. Smith and other Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international ...

PITTSBURGH, April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and will become a member of the company's Executive Leadership Team, effective today. Le Goff is an accomplished biotechnology and pharmaceutical executive with more than 25 years of experience leading and building highly successful teams globally. She is a visionary and entrepreneurial leader with a strong scientific bac ...

Vertigo3d There is quite a pronounced valuation gap in the pharmaceuticals sector, with richly priced names like Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO) on the high-end of the spectrum, and others like Bristol Myers Squibb Company (BMY) and Gilead Sciences, Inc. (GILD) on the other end. This brings me to the even lower-priced name, Viatris Inc. (NASDAQ:VTRS) which falls in the deep value category. I last covered VTRS back in June of last year, noting that it wouldn't take much to move the nee ...

PITTSBURGH, April 1, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists (e.g., phenylephrine) or parasympatholytic (e.g., tropicamide) agents in the United States. RYZUMVI is now the only U.S. commercially available FDA-approved eye drop to reverse dilation.1 According to the American Academy of Op ...

Viatris Inc. (NASDAQ:VTRS) R&D Event March 27, 2024 10:00 AM ET Company Participants Bill Szablewski - Head of Capital Markets Scott A. Smith - Chief Executive Officer Rajiv Malik - President Philippe Martin - Chief R&D Officer Deepak L. Bhatt - Director of Mount Sinai Fuster Heart Hospital Anca Askanase - Founder and Clinical Director of Columbia University No Lupus Center Doretta Mistras - Chief Financial Officer Conference Call Participants Jason Gerberry - Bank of America Glen Santangelo - Jefferies Nat ...